Epic Sciences Stock

epicsciences.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $24MM

Epic Sciences, founded in 2008, is a diagnostics company seeking to to improve cancer management. The company aims to provide easily accessible and real-time biopsy material to guide personalized medicine for numerous pharmaceutical companies and major cancer centers. The Epic Sciences platform is designed with the goal of identifying and characterizing rare cells including circulating tumor cells ("CTCs"). Epic Sciences is headquartered in San Diego, California.

Register for Details

For more details on financing and valuation for Epic Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Epic Sciences.

Register Today

Epic Sciences investors also invested in these private companies

Domain Associates
Pagoda Investment
U.S. Department of Health and Human Services
Arcus Ventures
Labcorp Ventures
Altos Capital Partners
Genomic Health
Hermed Capital
VI Ventures


Management Team

Pascal Bamford Ph.D
Chief Scientific Officer and Head of Laboratory Operations
Dena Marrinucci Ph.D
Co-Founder & Member Clinical Advisory Board
Murali Prahalad Ph.D
Chief Executive Officer & President
Ryan Dittamore
Chief of Medical Innovation and Head of Translational Research Partnerships
Ian Miller JD
Chief Business Officer and General Counsel
Dave Henderson
Chief Information Officer

Board Members

Evgeny Zaytsev Ph.D
Kim Kamdar Ph.D
Domain Associates
Andrew ElBardissi MD
Deerfield Management
Simon Greenwood Ph.D
Roche Venture Fund

Other companies like Epic Sciences in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC
Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months.
Epic Sciences Closes $52M in Series E Financing | FinSMEs
Epic Sciences, a San Diego, CA-based developer of blood tests that predict therapeutic benefit for cancer patients, completed a $52m Series E financing
Updated on: Sep 24, 2023